Eligibility, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Blood PressurePrimary· Control period is 6 months before the intervention and intervention period is up to 6 months after the intervention
Systolic and diastolic blood pressure of patients treated by the participating clinician trainees as reported in the Electronic Medical Record.
Systolic Blood Pressure
Group
Value
95% CI
Patients - Pre CONSULT-BP Intervention
137.6
± 18.6
Patients - Post-Intervention
136.4
± 18.6
Diastolic BloodPressure
Group
Value
95% CI
Patients - Pre CONSULT-BP Intervention
82.1
± 11.1
Patients - Post-Intervention
81.8
± 10.8
RELATE Checklist, a Standardized Patient Rating Scale for Bias-Mitigating and Patient-Centered CommunicationSecondary· During CONSULT-BP session 2 clinician training intervention (simulated standardized patient encounter)
The RELATE (Respect, Empathize, Listen, Ask, Talk, Engage) is a 19-item checklist completed by an informant group of "standardized" patients during a simulated standardized patient encounter to evaluate interaction with the participating clinicians. The RELATE checklist contains 4 factors: Respect (4 items), Empathetic Listening (5 items); Ask and Talk (Inquiry, 6 items), and Engagement in Partnership (4 items). The checklist scores are from 0 to 38, with higher scores reflecting better communication from the perspective of the "standardized" patient.
Group
Value
95% CI
Healthcare Trainees
32.7
± 5.0
Sponsor's own description
The goal of CONSULT-BP is to train early-stage healthcare providers, including residents and nurse practitioner (NP) students, to mitigate providers' bias, improve communication skills, and enhance providers' ability to develop authentic and meaningful therapeutic alliances with patients. The study setting is an academic safety net hospital that serves a large non-White and poor population. The Investigators hypothesize that patients' outcomes (blood pressure levels) will be lower after the training intervention compared with before training (control) periods.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A
· NA
· recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S
· recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
· NA
· recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia
· Phase 2
· recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension
· NA
· recruiting
Other University of Massachusetts, Worcester trials
Trials by the same sponsor.
NCT07431528 — Dementia and Storytelling in Vietnam
· NA
· not yet recruiting
NCT07060664 — Study on Outcomes of Proximal Humerus Fractures
· NA
· not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
· Phase 3
· not yet recruiting
NCT06100809 — Does Fatigue Coaching Improve Functioning and Fatigue in Resident Night Shifts
· NA
· not yet recruiting
NCT06246539 — Impact of a Virtual Reality-based Mindfulness Program on Clinician Wellness
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Massachusetts, Worcester
Last refreshed: 19 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03375918.